Tikehau Capital has acquired a minority stake in Medtrade
Founded in 1999, Medtrade is a dynamic medical device developer and ISO certified manufacturer of advanced wound care and consumer healthcare products. The company, with this investment, is positioned to grow strongly within the $9.8bn advanced wound care market as well as expand it’s haemostat offering through leveraging its industry-leading Celox technology.
The company operates through three divisions being (i) Advanced Wound Care division, which is a private label wound care business which develops and manufactures wound care products such as foam formats, gelling fibre formats and spray bandages on behalf of a select group of blue chip customers (ii) Trauma division, which operates in the fast growing military and emergency medical markets, manufacturing high performance hemostatic wound care technologies and (iii) Hospital Haemostats and New Technology Investments division which focuses on earlier stage technologies leveraging Medtrade’s proprietary Celox technology.
Matthew Lee, Managing Director and head of Lincoln’s UK Healthcare Group, commented, “We are delighted to have supported Tikehau Capital make this investment in what is an exciting UK based medical technology business. Tikehau Capital are a prolific investor, having invested in 5 deals out of their pan-European growth equity fund in less than 12 months, with this transaction representing Lincoln’s 1st UK mandate with Tikehau Capital, the UK Healthcare team’s 2nd announced transaction in 2019 and Lincoln’s 2nd medical technology deal announcement in the same week.”
Tikehau Capital brings to the table real industry understanding and value adding relationships which I am convinced will be brought to bear to help Medtrade’s management deliver on their ambitious plans.
Meet our Senior Team
View More Transactions
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.